SOUTH EASTON, Mass.,
Dec. 11, 2013 /PRNewswire/ --
Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the
"Company") today announced that Merriman Capital, Inc.
("Merriman"), a wholly owned subsidiary of Merriman Holdings, Inc.
(OTCQX: MERR), will host an investor call for PBI on Thursday, December 12, 2013 at 4:30 p.m. EST. Pressure BioSciences CEO
Richard T. Schumacher and Board
Chairman Jeffrey N. Peterson will
provide an update on the Company, including a review of the
achievements of 2013 and stated goals for 2014, via a webcast with
an accompanying PowerPoint presentation.
All investors and interested parties are welcome to join the
conference call and webcast. A question and answer session will
follow the opening remarks and presentation. Mr. Schumacher,
Mr. Peterson, and board members Mr. Vito
Mangiardi, Mr. Kevin Pollack,
and Dr. Mickey Urdea will be
available during the Q&A session.
Conference Call, Webcast and Presentation Information
Date: Thursday, December 12,
2013
Time: 4:30 PM Eastern Standard
Time (EST)
To listen to this teleconference via telephone (whether or not
watching the webcast):
Dial-in: (800) 875-3456 (U.S.); (800) 648-0973 (Canada); (302) 607-2001 (International)
Passcode: VS87265 Conference ID:
865561
To view the webcast, use the following conference link (NOTE:
you must use the call-in number above for the audio portion of the
webcast):
http://www.join.me/pbio.investormeeting.M1.
The PBIO presentation will be available for viewing and
downloading as of 10 a.m. EST,
Thursday, December 12, 2013 on the
Company's website:
http://www.pressurebiosciences.com.
For those unable to participate in the live teleconference, a
replay will be available approximately one hour after the call and
will be accessible through the Company's website for 30
days.
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. ("PBI") (OTCQB: PBIO) is focused on
the development, marketing, and sale of proprietary laboratory
instrumentation and associated consumables based on Pressure
Cycling Technology ("PCT"). PCT is a patented, enabling
technology platform with multiple applications in the estimated
$6 billion life sciences sample
preparation market. PCT uses cycles of hydrostatic pressure
between ambient and ultra-high levels to control bio-molecular
interactions. PBI currently focuses its efforts on the
development and sale of PCT-enhanced sample preparation systems
(instruments and consumables) for mass spectrometry, biomarker
discovery, bio-therapeutics characterization, vaccine development,
soil and plant biology, forensics, histology, and counter-bioterror
applications.
About Merriman Capital, Inc.
Merriman Capital, Inc. is a full service investment bank and
Broker-Dealer that facilitates efficient capital formation through
a proprietary digital network, as well as Capital Markets Advisory
and comprehensive Corporate Brokerage services for public and
private companies. The firm also provides equity and options
execution services for sophisticated investors and differentiated
research for high growth companies. Merriman Capital, Inc. is a
wholly owned brokerage subsidiary of Merriman Holdings, Inc.
(OTCQX: MERR) and is a leading advisory firm for publicly traded,
high-growth companies.
Merriman Capital, Inc. is a registered broker-dealer and member
of The Financial Industry Regulatory Authority (FINRA)
http://www.finra.org/ and the Securities Investor Protection
Corporation (SIPC) http://www.sipc.org/.
Forward Looking Statements
This press release contains forward-looking statements. These
statements relate to future events or our future financial
performance and involve known and unknown risks, uncertainties and
other factors that may cause our or our industry's actual results,
levels of activity, performance or achievements to be materially
different from any future results, levels of activity, performance
or achievements expressed, implied or inferred by these
forward-looking statements. In some cases, you can identify
forward-looking statements by terminology such as "may," "will,"
"should," "could," "would," "expects," "plans," "intends,"
"anticipates," "believes," estimates," "predicts," "projects,"
"potential" or "continue" or the negative of such terms and other
comparable terminology. These statements are only predictions based
on our current expectations and projections about future events.
You should not place undue reliance on these statements. In
evaluating these statements, you should specifically consider
various factors. Actual events or results may differ materially.
These and other factors may cause our actual results to differ
materially from any forward-looking statement. These risks,
uncertainties, and other factors include, but are not limited to,
the risks and uncertainties discussed under the heading "Risk
Factors" in the Company's Annual Report on Form 10-K for the year
ended December 31, 2012, and other
reports filed by the Company from time to time with the SEC. The
Company undertakes no obligation to update any of the information
included in this release, except as otherwise required by law.
For
more information about PBI and this press release, please click on
the following website link:
Please
visit us on: Facebook, LinkedIn, and Twitter.
http://www.pressurebiosciences.com
Investor Contacts:
Richard T. Schumacher, President
& CEO, Pressure BioSciences,
Inc. (508)
230-1828 (T)
Douglas Rogers, Managing Director,
Merriman Capital,
Inc. (415)
248-5612 (T)
SOURCE Pressure BioSciences, Inc.
